Author:
Choi Eunyoung,Koo Taeyoung
Publisher
Springer International Publishing
Reference60 articles.
1. Neri, M., Torelli, S., Brown, S., Ugo, I., Sabatelli, P., Merlini, L., Spitali, P., Rimessi, P., Gualandi, F., Sewry, C., Ferlini, A., & Muntoni, F. (2007). Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscular Disorders, 17, 913–918. https://doi.org/10.1016/j.nmd.2007.07.005
2. Beggs, A. H., Hoffman, E. P., Snyder, J. R., Arahata, K., Specht, L., Shapiro, F., Angelini, C., Sugita, H., & Kunkel, L. M. (1991). Exploring the molecular basis for variability among patients with Becker muscular dystrophy: Dystrophin gene and protein studies. American Journal of Human Genetics, 49, 54–67.
3. Lim, K. R. Q., Maruyama, R., & Yokota, T. (2017). Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Design, Development and Therapy, 11, 533–545. https://doi.org/10.2147/DDDT.S97635
4. Heo, Y. A. (2020). Golodirsen: First approval. Drugs, 80, 329–333. https://doi.org/10.1007/s40265-020-01267-2
5. Roshmi, R. R., & Yokota, T. (2021). Pharmacological Profile of viltolarsen for the treatment of duchenne muscular dystrophy: A Japanese experience. Clinical Pharmacology: Advances and Applications, 13, 235–242. https://doi.org/10.2147/CPAA.S288842
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献